Ayala Healthcare Holdings Inc., a unit of the Ayala Corp., expanded its digital portfolio with the recent investment in US-based healthcare technology firm Fibronostics.
AC Health, though technology arm Vigos, signed a partnership agreement with SPRIM Ventures, the bioscience R&D firm spun off by Fibronostics.
AC Health, however, did not disclose additional details on the transaction, including how much stake it acquired in Fibronostics and the value of the transaction.
“This investment fits well into our Vigos health technology portfolio, which we are proud to say is the first digital health portfolio in the Philippines. We are always on the lookout for technology solutions that empower our doctors and improve quality for our patients,” said AC Health president and chief executive Paolo Borromeo.
Founded in 2015, Fibronostics focuses on non-invasive algorithm-based solutions for diagnostic testing. It aims to improve screening, follow-up and diagnosis through non-invasive products. Key focus areas include prevalent chronic conditions such as liver disease, coronary heart disease, stroke, diabetes and obstructive sleep apnea.
AC Health said it would launch two Fibronostics products, LiverFAST and HealthFACTR in its FamilyDOC clinics as part of the partnership.
LiverFAST is a proprietary algorithm that analyzes 10 biomarkers from a blood sample to help screen and monitor common liver diseases. The test is intended to be a simple and less expensive option to other diagnostics, such as liver biopsy or liver imaging.
HealthFACTR, meanwhile, is as a 10-minute metabolic health check-up solution that provides immediate risk assessment and personalized recommendations, based on the latest medical guidelines.